Dureach

Acrigen Biosciences

United States
NameAddress
Salem, South Dakota, United States
https://www.acrigen.com/

Company profile

Acrigen Biosciences company profile

Acrigen Biosciences is dedicated to making gene editing safe. It develops technologies to improve efficiency and enhance the safety of CRISPR-Cas based gene editing. CRISPR-Cas system which enables the precise enzymatic editing of genes is one of the most exciting and promising techniques to be developed in the last few years with the capability to prevent or cure many devastating diseases. It was founded in 2019 and is headquartered in Berkeley, California.

Business identity

Website
https://www.acrigen.com/
Operating status
Active
Company type
For Profit
Employee range
00001-00010 employees
Revenue range
$1K+
Founded
2019-01-01
LinkedInX

Headquarters

Headquarters
Salem, South Dakota, United States
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
3
Last funding
Grant / $1M / 2022-02-24
Last equity funding
Seed
Investors
5
Lead investors
2
Founders
2
Articles
6

Categories and groups

BiotechnologyGeneticsLife ScienceBiotechnologyHealth CareScience and Engineering

Founders and investors

Founders

David RabukaJoe Bondy-Denomy

Lead investors

National Science FoundationRed Tree Venture Capital

Investors

Alexandria Venture InvestmentsBerkeley Catalyst Fund (BCF)Dolby Family VenturesNational Science FoundationRed Tree Venture Capital

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.